InVivo Analytics has received $1.7 million to develop and commercialize its next-generation fluorescence imaging device, called InVivoFLUOR, for 3D monitoring of immune cell migration in animal models of cancer, the company announced in a press release. Company researchers plan to validate the system on a mouse model of ovarian cancer. Animals will be treated with an advanced immunotherapy, developed at the the University of Washington, that activates T-cells against ovarian cancer cells. The grant is…
You must be logged in to read/download the full post.
The post InVivo Analytics Granted $1.7M to Advance Preclinical 3D Imaging appeared first on BioNewsFeeds.